home / stock / avhhl / avhhl news

AVHHL News and Press, Avita Therapeutics From 11/09/23

Stock Information
Company Name: Avita Therapeutics
Stock Symbol: AVHHL
Market: OTC
Website: avitamedical.com
Menu
AVHHL AVHHL Quote AVHHL Short AVHHL News AVHHL Articles AVHHL Message Board
Get AVHHL Alerts

News, Short Squeeze, Breakout and More Instantly...
AVHHL - AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year

VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “ Company ”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, tod...
AVHHL - AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe

VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today ann...

AVHHL - AVITA Medical to Announce Third Quarter 2023 Financial Results

VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its...

AVHHL - AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives

Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed $40 million funded at close; $50 million of additional non-dilutive capital available at the Company’s option, based on the achievement of certain revenue thresholds Capita...
AVHHL - AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma

VALENCIA, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, is pleased to announce that the RECELL...

AVHHL - AVITA Medical to Present at the Cantor Global Healthcare Conference

VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chie...

AVHHL - AVITA Medical to Participate in Upcoming Investor Conferences

VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that its management te...
AVHHL - AVITA Medical, Inc. (RCEL) Q2 2023 Earnings Call Transcript

2023-08-10 22:47:07 ET AVITA Medical, Inc. (RCEL) Q2 2023 Earnings Conference Call August 10, 2023, 04:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Confere...

AVHHL - AVITA Medical Reports Second Quarter Financial Results

VALENCIA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “ Company ”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, tod...

AVHHL - AVITA Medical to Announce Second Quarter 2023 Financial Results

VALENCIA, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its...
Previous 10 Next 10